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The physiological effects of opioid receptor agonists (ORAs) mediated by their activation of either µ-, δ-or κ-opioid receptors have been well characterized.
We previously reported peripheral, visceral antinociceptive actions produced by arylacetamide κ-ORAs like U50,488 and EMD 61,753. These drugs dosedependently attenuated responses of rat pelvic nerve afferent fibers to noxious distension of the colon or bladder (Su et al., 1997a; Su et al., 1997b; Sengupta et al., 1996) . Such peripheral, visceral antinociceptive effects were resistant to antagonism by traditional KOR antagonists like nor-BNI, DIPPA and high-dose naloxone, and were interpreted to be opioid receptor-independent. Further support for this interpretation derives from experiments performed in rats in which the κ-opioid receptor (KOR) was 'knocked-down' at peripheral somatic and colonic sites using antisense oligodeoxynucleotides (Joshi et al., 2000) .
Although κ-ORA-produced somatic antinociception was blocked by KOR antisense treatment, κ-ORAs could still dose-dependently inhibit responses of pelvic nerve afferent fibers to noxious colon distension in the same KOR antisense-treated rats. Other reports have also described opioid receptorindependent pharmacological actions of κ-ORAs in the cardiovascular (see Pugsley, 2002 for review) and nervous systems (Alzheimer and ten Bruggencate, 1990; Su et al., 2002) , including ion channel blocking effects on voltage-gated calcium, potassium and sodium channels.
In particular, κ-ORAs with an arylacetamide structure have been documented in a series of experiments to be antiarrhythmic by a blockade of 5 cardiac sodium channels (Pugsley et al., 1993; Pugsley et al., 1994; Pugsley et al., 2000a; Pugsley et al., 2000b) . The sodium channel blocking action of arylacetamice κ-ORAs persists in the presence of opioid receptor antagonists (Pugsley et al., 1994) . When tested in heterologous expression systems without endogenous opioid receptors, the inhibition of sodium currents by such κ-ORAs also persists (Pugsley et al., 2000b) . Additionally, the sodium channel blocking action of arylacetamide κ-ORAs is also seen with enantiomers of κ-ORAs that lack activity at opioid receptors (Pugsley et al., 1993) . Such observations support the notion that the sodium channel blockade produced by arylacetamide κ-ORAs occurs by a mechanism independent of their actions at the κ-opioid receptor (KOR).
Primary sensory neurons express several voltage-gated sodium channels, some of which are resistant to blockade by tetrodotoxin (TTX) (Black et al., 1996; Bielefeldt, 2000; Elliott and Elliott, 1993; Schild and Kunze, 1997; Bielefeldt et al., 2002) . Recent studies suggest that TTX-resistant sodium channels play an important role in nociception, particularly in circumstances where nociceptor excitability is increased after tissue injury (Lai et al., 2002; Bielefeldt et al., 2002) .
Because κ-ORAs may be useful in management of discomfort and pain that characterize functional gastrointestinal disorders, we examined the effects of κ-ORAs on TTX-sensitive and TTX-resistant sodium currents in colon sensory neurons.
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METHODS
Experimental animals and DiI labeling
All experiments were performed on male Sprague Dawley rats (age 2-3 months; Harlan, Indianapolis, IN). Animals were housed 1-2 per cage with free access to food and water, and were maintained on a 12 hr light-dark cycle in the AAALAC approved animal care facility. All experimental protocols were approved by the Institutional Animal Care and Use committee, The University of Iowa.
To label colon sensory neurons, rats were anesthetized with sodium pentobarbital (50 mg/kg intraperitoneally). The descending colon was surgically exposed and the retrograde tracer DiI (1.1'-dioctadecyl-3,3,3,'3'-tetramethylindocarbocyanine metanesulfonate; 25 mg/0.5 ml methanol) was injected into 15-20 sites (1-2 µl/site, 30 µl total) into the wall of the descending colon using a 30-gauge needle. Each injection site was washed with saline to minimize contamination of the adjacent areas with dye. Animals were allowed to recover for 10-14 d following the surgery to allow dye to be transferred to the cell somas of colon sensory neurons in the S1 dorsal root ganglion (DRG).
Cell Dissociation and Culture
Rats were deeply anesthetized with sodium pentobarbital (50 mg/kg intraperitoneally) and the S1 DRG were quickly removed and transferred into icecold culture media. 
Electrophysiological recordings
Cells attached to coverslips were transferred into a 0.5 ml recording chamber onto a stage of an inverted microscope. Colon sensory neurons were identified by observation of their red orange color in fluorescent light with rhodamine filter (excitation wavelength ~546 nm and barrier filter at 580 nm).
Each culture dish usually contained about 2-4 labeled cells among a few hundred unlabelled neurons, and only labeled neurons were selected for study. Sodium currents were recorded using the whole cell patch clamp technique with an Axopatch 200A amplifier (Axon Instruments, Foster City, CA) interfaced with a 8 personal computer. The patch pipettes were pulled from a thin walled borosilicate glass with tip resistances of 1-3 MΩ after fire polishing. Current recordings were filtered at 2 KHz digitized at 10 KHz using a Digidata 200 interface (Axon Instruments), and the series resistance and whole cell capacitance were compensated > 80% in all experiments. The passive membrane properties were monitored during the course of the experiments and cells were used for analysis only if these properties were stable. Signals were stored on a computer for later analysis. Voltage protocols were generated, the data acquired and analyzed using the software package pCLAMP 6.0 (Axon Instruments). The leak current and residual capacitative transients were digitally subtracted using p/n protocol for leak subtraction with p being the test pulse and n=4. Dynorphin 1-13 and different doses of U50,488 and EMD 61,753 were perfused into the bath to study their effects on sodium currents. All experiments were performed at room temperature (21 0 C).
Solutions and Chemicals
To isolate sodium currents, the pipette solution contained the following (in 
Data Analysis
All data are expressed as mean ± SEM. The data were analyzed using Students' t-test. The concentration of drugs producing a 50% inhibition of peak currents (IC 50 ) was calculated using the program GraphPad Prism (version 2). A value of p<0.05 was considered statistically significant.
RESULTS
Effects of U50,488 and EMD 61,753 on voltage activated sodium currents (VASCs)
In initial control experiments, the peak sodium current did not show significant run down over a time course of 20 min under the experimental conditions chosen (102 ± 2 % control; n = 6). To study the effects of arylacetamide κ-ORAs on VASCs, voltage steps of 40 ms duration were applied every 20 s from a resting potential of -70 mV to a test potential of 10 mV.
Different concentrations (10 -9
-10 -4 M) of U50,488 or EMD 61,753 were perfused into the bath, peak inward currents were analyzed in the absence and presence of these drugs, and the fractional block of sodium current at each concentration was plotted against the concentration of drug. Fig. 1A shows the concentrationresponse curves for U50,488 and EMD 61,753 in blocking VASCs from colon sensory S1 DRG neurons. Both drugs produced a concentration-dependent inhibition of peak sodium current. The concentrations of U50,488 and EMD 61,753 causing a half-maximal block of peak sodium current (IC 50 ) were 8.4 ± 1.69 µM and 1.2 ±1.78 µM, respectively. In contrast to the effects of U50,488
and EMD 61,753, the peptide κ-ORA dynorphin 1-13 at a concentration of 10 -5 M was ineffective in inhibiting VASCs (Fig. 1B) .
We separated sodium currents based on their biophysical properties.
TTX-sensitive (TTX-S) sodium currents have a voltage of half-inactivation of about -70 mV (Cummins and Waxman, 1997; Bielefeldt et al., 2002) and are essentially fully inactivated at voltages higher than -40 mV. In contrast TTXresistant (TTX-R) sodium currents inactivate at more depolarized potentials with a voltage of half-inactivation around -25 mV (Cummins and Waxman, 1997; Bielefeldt et al., 2002) . Using a prepulse inactivation protocol with a 750 ms step to -40 mV, we were able to isolate the TTX-R sodium current (Cummins and Waxman, 1997; McLean et al., 1988; Roy and Narahashi, 1992) . Digital subtraction of this current from the total sodium current reveals the TTX-S current that has a faster onset of activation and inactivation ( Fig. 2A) . To test the validity of this approach in colon sensory neurons, we compared the relative contribution of the TTX-R current determined electrophysiologically with results obtained in the presence of 1 µM TTX (Su et al., 1999) . Figure 2B shows the close correlation between both measures. While most cells expressed both TTX-R and TTX-S sodium currents, a predominance of one of the pharmacologically distinct sodium currents was found in about one third of the cells (Fig. 2C) . As most of the neurons studied were small with a whole cell capacitance of 30.0 ± 1.1 pF, we were not able to examine the relationship between cell size and sodium current properties. While we relied on the distinction of these current components using electrophysiological rather than pharmacological tools in the experiments described below, we will still refer to the current component as TTX-R and TTX-S throughout the text. Figure 3 illustrates that U50,488 and EMD 61,753 produce a concentration-dependent inhibition of both TTX-S and TTX-R components of the total sodium current, and were thus non-selective in their blockade.
Effect of U50,488 on the voltage dependence of steady state inactivation of VASCs
To study the effects κ-ORAs on the voltage dependence of inactivation,
we chose a concentration of U50,488 (10 -5 M) that produced a marked block of VASCs. For these experiments, cells were held at conditioning potentials between -110 mV and 10 mV for 750 ms before stepping to a test potential of 10 mV. The peak current amplitude was normalized to maximum current amplitude, and plotted as a function of the conditioning prepulse potential in the absence and presence of 10 -5 M U50,488 (Fig. 4A ). The effect of U50,488 on the inactivation of the TTX-S sodium current was determined by electrophysiologically separating the two fractions from the total sodium current by digitally subtracting the current obtained after a prepulse to -40 mV from the current traces at more negative potentials (see above). Five cells expressed more than 80% TTX-R sodium current and were used to examine the steady state inactivation. The results of the electrophysiologically distinct currents were fit with the Boltzmann equation. Under control conditions, the voltages of halfinactivation were -59.8 ± 2.8 mV (n = 6) and -23.5 ± 1.2 mV (n = 5) for the TTX-S and TTX-R sodium current, respectively. U50,488 shifted the steady state voltage dependence of inactivation curves for total (Fig. 4A ), TTX-S (Fig. 4B ) and TTX-R (Fig. 4C ) sodium currents to more negative potentials. As shown in figures 4B and 4C, the inactivation curves in the presence of U50,488 exhibited distinct shoulders, not allowing a good fit with the Boltzmann equation.
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Use-dependent block of VASCs by U50,488
We also examined the ability of U50,488 (10 -5 M) to induce a usedependent block of VASCs. Five minutes after administration of U50,488 or vehicle, repetitive stimulation was applied to the cells with 5 ms depolarizing pulses at a frequency of 3 Hz. The evoked peak currents were normalized to the current during the first depolarization (pulse 1) and plotted as a function of pulse number. The peak currents measured in the presence of U50,488 were normalized to the current during the first depolarization in the presence of the drug to emphasize the amount of use-dependent block, independent of the tonic block produced by U50,488. We studied use-dependent block produced by U50,488 in neurons exhibiting a combination of currents (Fig 5A) , only TTX-R current ( Fig 5B) and only TTX-S current ( Fig 5C) as judged by the previously described biophysical characteristics. Repetitive stimulation enhanced the inhibition following the tonic block of total, TTX-S and TTX-R currents by 43.8 ± 4.9 (n=12), 46.2 ± 4.9 (n=3) and 40 ± 3.2 % (n=6), respectively, by the final pulse, demonstrating the ability of U50,488 to induce a significant use-dependent block of VASCs (p<0.05).
DISCUSSION
The experiments described confirm that arylacetamide κ-ORAs exhibit voltage-gated sodium channel blocking properties in primary colon sensory neurons . The key novel findings relate to the effect of these agents on physiologically distinct sodium currents and their mechanisms of action. Interestingly, the potencies of U50,488 and EMD61,753 on the TTX-R current were not appreciably different than their potencies on the TTX-S component of the current.
Sodium channel blocking actions of arylacetamide κ-ORAs in primary sensory neurons
U50,488 and EMD 61,753 concentration-dependently decreased TTX-S and TTX-R sodium currents. In contrast, the peptide κ-ORA dynorphin 1-13 was without effect in these experiments. The concentrations required to achieve inhibition are consistent with previously published studies examining the effects of arylacetamide κ-ORAs on neuronal (Alzheimer and ten Bruggencate, 1990; Su et al., 2002) or cardiac VASCs (Pugsley et al., 2000b) . Previous studies have
shown that this inhibition of VASCs by arylacetamide κ-ORAs is at least in part due to a use-dependent block of VASCs (Pugsley et al., 1994; Pugsley et al., 2000a; Su et al., 2002) . Additionally, they cause a hyperpolarizing shift in the voltage dependence of inactivation curve of sodium currents (Pugsley et al., 1994; Pugsley et al., 2000a) . Such sodium channel blocking mechanisms are analogous to those reported for local anesthetics like lidocaine, which shares structural similarities with arylacetamide κ-ORAs (Pugsley et al., 2000b) .
We examined the mechanisms underlying sodium channel inhibition in primary sensory neurons using one of the arylacetamide κ-ORAs, U50,488. The voltage-dependence of inactivation was shifted by U50,488 to more hyperpolarized potentials. As shown in Fig. 4 , significant inactivation occurred at voltages more negative than -80 mV. This became especially prominent in cells primarily expressing TTX-R current, which normally does not inactivate at prepulse potentials negative of -50 mV. These findings are consistent with an enhanced transition from the closed to the inactivated state (Bean et al., 1983) in the presence of the arylacetamide κ-ORA. Comparable findings have been described for cardiac (Pugsley, et al., 1994) and heterologously expressed neuronal sodium channels (Pugsley et al., 2000a) . This increased closed state inactivation underlies the tonic inhibition component seen following drug administration.
However, other mechanisms may contribute to the inhibitory effects of arylacetamide κ-ORAs (Pugsley et al., 1994; Pugsley et al., 2000a; Su et al., 2002) . We examined whether U50,488 caused a use-dependent block, using a repetitive stimulation protocol. While brief depolarizations to 10 mV at a frequency of 3 Hz did not lead to a cumulative inhibition under control conditions, the peak sodium current progressively decreased in the presence of the κ-ORA.
This use-dependent inhibition was similar in both TTX-S and TTX-R VASCs. The presence of use-dependent inhibition, often also referred to as phasic channel block, suggests that κ-ORAs also interact with the open channel, favoring a transition into the closed state or directly acting on the exposed pore of the ion channels. Local anesthetics lead to similar tonic and phasic inhibition of sodium currents by enhancing transitions into the closed state and slowing reactivation (Courtney, 1975; Wagner et al., 1999) .
Peripheral, visceral analgesic actions of arylacetamide κ-ORAs
Previous findings obtained in vivo are consistent with a peripheral, opioid receptor-independent mechanism of action for arylacetamide κ-ORAs. Whereas µ-, δ-and peptide κ-ORAs were ineffective when tested for peripheral effects in models of visceral nociception, arylacetamide κ-ORAs exhibited potent antinociceptive effects (Sengupta et al., 1996; Su et al., 1997a; Su et al., 1997b , Ozaki et al., 2000 . Opioid receptor antagonists or intrathecal treatment with antisense oligodeoxynucleotides targeting the KOR (Joshi et al., 2000) did not inhibit the peripheral, visceral antinociceptive actions of arylacetamide κ-ORAs.
Arylacetamide κ-ORAs, including enantiomers of U50,488 with no efficacy as κ-ORAs in KOR antisense-treated animals produce, are antinociceptive at peripheral cutaneous sites like the hind paw, but only at doses higher than those required to activate the KOR (Joshi and Gebhart, in press ).
Significance of findings
Sodium channels play a significant role in the perception of noxious sensation arising from the viscera (Bielefeldt et al., 2002;  underlie the activation of primary afferent nerves after inflammation of bladder, colon and stomach by chemical irritants (Bielefeldt et al., 2002; Beyak et al., 2003) . (Tanelian and Brose, 1991; Wagner et al., 1999) . Electrophysiological separation of TTX-S and TTX-R components of the total sodium current. Total sodium current was obtained using a 750 ms prepulse to -110 mV before applying the test pulse to 10 mV. Using a prepulse inactivation protocol with a 750 ms step to -40 mV, the TTX-R sodium current was isolated.
Digital subtraction of this current from the total sodium current reveals the TTX-S current that has a faster onset of activation and inactivation. B, Results of the electrophysiological isolation of TTX-R sodium currents with a prepulse to -40 mV (expressed as fraction of the total sodium current) significantly correlated 26 with the effects of 1 µM TTX (from Su et al., 1999 , expressed as faction of the total sodium current; n = 24). C, The relative contribution of TTX-S sodium current to the total sodium current was examined using 1 µM TTX, demonstrating a mixed current in most cells. ms depolarizing pulses from a resting potential of -70 mV to a test potential of 10 mV at a frequency of 3 Hz was given in the presence and absence of drug. The peak currents were normalized to the currents during the first depolarization (pulse 1) and plotted as a function of pulse number. The peak currents plotted in the presence of the drug were normalized to the current during the first depolarization in the presence of the drug. A progressive decrease in currents with repetitive stimulation is observed following perfusion of U50,488. The ratio of current amplitude at the final pulse decreased significantly to ~ 40% for the total, TTX-S and TTX-R sodium currents (p<0.05).
